GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Cizzle Biotechnology Holdings PLC (LSE:CIZ) » Definitions » Debt-to-Asset

Cizzle Biotechnology Holdings (LSE:CIZ) Debt-to-Asset : 0.00 (As of Jun. 2024)


View and export this data going back to 2021. Start your Free Trial

What is Cizzle Biotechnology Holdings Debt-to-Asset?

Cizzle Biotechnology Holdings's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Jun. 2024 was £0.00 Mil. Cizzle Biotechnology Holdings's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Jun. 2024 was £0.00 Mil. Cizzle Biotechnology Holdings's Long-Term Debt & Capital Lease ObligationTotal Assets for the quarter that ended in Jun. 2024 was £0.92 Mil. Cizzle Biotechnology Holdings's debt to asset for the quarter that ended in Jun. 2024 was 0.00.


Cizzle Biotechnology Holdings Debt-to-Asset Historical Data

The historical data trend for Cizzle Biotechnology Holdings's Debt-to-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Cizzle Biotechnology Holdings Debt-to-Asset Chart

Cizzle Biotechnology Holdings Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Debt-to-Asset
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Cizzle Biotechnology Holdings Semi-Annual Data
Dec14 Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24
Debt-to-Asset Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Cizzle Biotechnology Holdings's Debt-to-Asset

For the Biotechnology subindustry, Cizzle Biotechnology Holdings's Debt-to-Asset, along with its competitors' market caps and Debt-to-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Cizzle Biotechnology Holdings's Debt-to-Asset Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Cizzle Biotechnology Holdings's Debt-to-Asset distribution charts can be found below:

* The bar in red indicates where Cizzle Biotechnology Holdings's Debt-to-Asset falls into.



Cizzle Biotechnology Holdings Debt-to-Asset Calculation

Debt to Asset measures the financial leverage a company has.

Cizzle Biotechnology Holdings's Debt-to-Asset for the fiscal year that ended in Dec. 2023 is calculated as

Cizzle Biotechnology Holdings's Debt-to-Asset for the quarter that ended in Jun. 2024 is calculated as

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Cizzle Biotechnology Holdings  (LSE:CIZ) Debt-to-Asset Explanation

In the calculation of Debt-to-Asset, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Assets.


Cizzle Biotechnology Holdings Debt-to-Asset Related Terms

Thank you for viewing the detailed overview of Cizzle Biotechnology Holdings's Debt-to-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.


Cizzle Biotechnology Holdings Business Description

Traded in Other Exchanges
N/A
Address
C/o SGH Secretaries Limited, 60 Gracechurch Street, 6th Floor, London, GBR, EC3V 0HR
Cizzle Biotechnology Holdings PLC is in the early stages of developing a blood test for the early detection of a majority of the different forms of lung cancer. Its proof-of-concept prototype test is based on the ability to detect a stable plasma biomarker, a variant of C1Z1 known as CIZ1B. C1Z1 is a naturally occurring cell nuclear protein involved in DNA replication, and the targeted C1Z1B variant is correlated with early stage lung cancer.

Cizzle Biotechnology Holdings Headlines